The COVID-19 medication Paxlovid does now not cut back the danger of lengthy COVID for vaccinated individuals who’ve examined certain for the virus for the primary time, in step with a brand new learn about by means of UCSF researchers.Brontë Wittpenn/The ChronicleThe COVID-19 medication Paxlovid does now not cut back the danger of lengthy COVID for vaccinated individuals who’ve examined certain for the virus for the primary time, in step with a brand new learn about by means of UCSF researchers.The learn about, revealed Thursday within the Magazine of Scientific Virology, additionally discovered {that a} upper proportion than in the past reported skilled rebound signs and examined certain for COVID after taking the antiviral drugs. The brand new learn about means that different COVID-19 prevention methods, like vaccination, overlaying and social distancing, “are nonetheless related,” mentioned one learn about writer, Dr. Matthew Durstenfeld, a heart specialist and UCSF assistant professor of medication.AdvertisementArticle continues underneath this advert“We have been shocked” by means of the learn about findings, Durstenfeld mentioned in a remark. “We anticipated that Paxlovid can be related to a decrease occurrence of lengthy COVID … however it’s in line with two different conscientiously carried out research discovering no distinction in post-COVID prerequisites between 4 and six months after an infection.”Researchers decided on a bunch of vaccinated other folks from UCSF’s COVID-19 Citizen Science Find out about who reported their first an infection between March and August 2022, in step with a UCSF information free up. A few of the 1,611 members, the learn about presentations the median age used to be 55 years and 66% have been feminine. Best probably the most members took oral Paxlovid medication whilst they have been inflamed. In December of that 12 months, members responded a survey about lengthy COVID, rebound signs and take a look at positivity, well being officers mentioned.From a bunch of people who reported feeling higher whilst taking Paxlovid medication, 21% reported rebound signs — 10.8% of whom reported a number of lengthy COVID signs when put next with 8.3% of people with out rebound signs, the learn about discovered.For many who repeated checking out after checking out detrimental and finishing medication, 25.7% reported rebound take a look at positivity once more. In general, researchers mentioned 26% mentioned they rebounded or examined certain.AdvertisementArticle continues underneath this adA identical learn about revealed in November discovered that viral rebound passed off in roughly 21% of Paxlovid recipients.“We discovered the next percentage with scientific rebound than in the past reported however didn’t determine an impact of post-treatment rebound on lengthy COVID signs,” Durstenfeld mentioned.Dr. Peter Chin-Hong, an infectious illness knowledgeable at UCSF who used to be now not concerned within the new learn about, mentioned its findings are “now not unexpected in any respect” since the chance of lengthy COVID amongst people who find themselves vaccinated and of their 50s used to be low first of all all through the omicron spike.“This learn about is helping us refine the inhabitants the place you’ll want to have the most important bang for the greenback in Paxlovid,” Chin-Hong mentioned. “It is still older or immunocompromised who’re unvaccinated or whom there isn’t a lot of an immune reaction as within the seriously immunocompromised.”Achieve Jessica Flores: jessica.flores@sfchronicle.com; Twitter: @jesssmfloresAdvertisementArticle continues underneath this advert
